Indian Court Strikes Down Novartis’ Patent Fight

Law360, New York (August 6, 2007, 12:00 AM EDT) -- In a blow to Novartis AG, an Indian court has rejected the Swiss drug maker’s controversial challenge to a key section of India’s patent laws, quelling an international uproar over whether the legal battle could block global access to affordable drugs.

The Madras High Court on Monday dismissed Novartis’ writ petition challenging the constitutionality of Section 3(d) of India’s Patents Amendment Act, which holds that molecules similar to existing molecules, such as derivatives of known substances, are ineligible for patents.

The court deferred to the World...
To view the full article, register now.